Bausch + Lomb (BLCO) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Bausch + Lomb published the results on October 28, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Bausch + Lomb reports EPS two ways: GAAP, under the accounting rules every US filer follows, and adjusted (non-GAAP), which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Bausch + Lomb is a subsidiary of Bausch Health Companies, which held approximately 88% of its common shares as of February 11, 2026. Bausch Health plans to separate Bausch + Lomb into an independent company.
• Bausch + Lomb reports in millions, so revenue and net income figures on this page are rounded to the nearest million as the release prints them.

Source: Bausch + Lomb Q3 2026 results, October 28, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Bausch + Lomb splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Bausch + Lomb's Vision Care revenue was $774 million in Q3 2026, up 5% from $736 million in Q3 2025, 56% of total revenue.
• Bausch + Lomb's Surgical revenue was $234 million in Q3 2026, up 9% from $215 million in Q3 2025, 17% of total revenue.
• Bausch + Lomb's Pharmaceuticals revenue was $367 million in Q3 2026, up 11% from $330 million in Q3 2025, 27% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

Bausch + Lomb gives its outlook as a table: full-year revenue of $5.450B to $5.550B (6.1% to 8.0% constant currency growth), up from $5.440B to $5.540B, and full-year adjusted EBITDA excluding acquired IPR&D of $1.090B to $1.140B, up from $1.025B to $1.075B.

In its Q3 2026 release, Bausch + Lomb said:

“The increase in the anticipated full-year revenue is a result of a $15 million increase in the underlying business outlook, based on continued strong business performance in the third quarter of 2026 and anticipated stronger business performance for the remainder of 2026, partially offset by a decrease of $5 million in expected currency tailwinds (such decrease is a result of exchange rates moderating).”

“Other than with respect to GAAP revenue, the company only provides guidance on a non-GAAP basis.”

Source: Bausch + Lomb Q3 2026 release, Oct 28, 2026.

This is the company's own guidance as of Oct 28, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the BLCO forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenues and basic and diluted EPS attributable to Bausch + Lomb Corporation, each as first reported in that quarter's release.

We do not hold a confirmed date for Bausch + Lomb's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 28, 2026

Bausch + Lomb's revenue rose 7% to $1,375 million in Q3 2026 from $1,281 million, and about 8% at constant currency after a $6 million foreign exchange headwind. Vision Care, which covers contact lenses and consumer eye care, was the largest segment at $774 million, up 5%. Pharmaceuticals brought in $367 million, up 11%, and Surgical $234 million, up 9%. (Bausch + Lomb Q3 2026 release, Oct 28, 2026)

By product category, over-the-counter products were $477 million of revenue, against $454 million, and devices were $517 million ($285 million in Vision Care and $232 million in Surgical), against $484 million. Prescription pharmaceuticals were $319 million, against $280 million, and branded and other generics $58 million. (Bausch + Lomb Form 10-Q, Q3 2026, Oct 28, 2026)

Bausch + Lomb named the drivers by brand. MIEBO revenue grew 42% to $119 million and international pharmaceuticals sales rose in Pharmaceuticals. Vision Care grew on daily SiHy lenses, up 24%, ULTRA lenses, LUMIFY, up 35%, and Artelac. Surgical growth came from premium intraocular lenses, which grew approximately 70%. (Bausch + Lomb Q3 2026 release, Oct 28, 2026)

Bausch + Lomb sells worldwide, but the U.S. and Puerto Rico are the largest market: $2,546 million of its $5,101 million of 2025 revenue. China was next at $358 million, then France at $246 million and Japan at $186 million. (Bausch + Lomb Form 10-K, 2025, Feb 18, 2026)

Bausch + Lomb's GAAP EPS was $0.09 in Q3 2026, against a loss of $0.08 a year earlier, on net income attributable to the company of $32 million against a $28 million loss. Adjusted EPS was $0.34, against $0.18. The gap is mostly amortization of intangible assets, $57 million or $0.16 per share, plus $17 million of restructuring, integration and transformation costs and $9 million of acquisition-related costs and adjustments. (Bausch + Lomb Q3 2026 release, Oct 28, 2026)

Operating income rose to $155 million from $95 million, which Bausch + Lomb attributed to revenue growth and operating efficiencies. Cost of goods sold fell to $485 million from $509 million; the year-ago figure included $19 million of fair value inventory step-up from acquisitions. Interest expense was $95 million, against $101 million, and the provision for income taxes was $23 million on pretax income of $58 million. (Bausch + Lomb Q3 2026 release, Oct 28, 2026)

Diluted weighted average shares were 361.5 million, against 354.2 million a year earlier. Share-based compensation, excluded from adjusted EBITDA, was $37 million in the quarter, against $27 million. (Bausch + Lomb Q3 2026 release, Oct 28, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Bausch + Lomb gives full-year guidance in its release on revenue and adjusted EBITDA excluding acquired IPR&D, and only revenue is on a GAAP basis. With Q3 2026 it raised full-year revenue guidance to $5.450B to $5.550B, or 6.1% to 8.0% constant currency growth, and adjusted EBITDA excluding acquired IPR&D to $1.090B to $1.140B. It gives no EPS guidance. (Bausch + Lomb Q3 2026 release, Oct 28, 2026)

The revenue increase reflects a $15 million rise in the underlying business outlook, partly offset by $5 million less expected currency tailwind. Bausch + Lomb now expects $40M of full-year revenue foreign exchange tailwinds, against $45M before. (Bausch + Lomb Q3 2026 release, Oct 28, 2026)

A consensus figure is the average of the models published by the analysts who cover Bausch + Lomb, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Bausch + Lomb's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning BLCO is on is BLCO a buy or a sell?, what analysts expect next is on the BLCO forecast, and what the company does is on the Bausch + Lomb (BLCO) stock page.

Every number on this page can be traced to a document Bausch + Lomb published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.